278 related articles for article (PubMed ID: 24343001)
21. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol.
LaGuardia KD; Shangold G; Fisher A; Friedman A; Kafrissen M
Contraception; 2003 Jun; 67(6):431-7. PubMed ID: 12814811
[TBL] [Abstract][Full Text] [Related]
22. Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.
Song IH; Borland J; Chen S; Wajima T; Peppercorn AF; Piscitelli SC
Ann Pharmacother; 2015 Jul; 49(7):784-9. PubMed ID: 25862012
[TBL] [Abstract][Full Text] [Related]
23. The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns.
Wooltorton E
CMAJ; 2006 Jan; 174(2):164-5. PubMed ID: 16368722
[No Abstract] [Full Text] [Related]
24. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
25. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick S; Kaye JA; Li L; Jick H
Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
[TBL] [Abstract][Full Text] [Related]
26. Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.
Rubio-Lotvin B; Gonzales-Ansorena R
Acta Eur Fertil; 1978 Mar; 9(1):1-6. PubMed ID: 696184
[TBL] [Abstract][Full Text] [Related]
27. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.
Sinofsky FE; Pasquale SA
Am J Obstet Gynecol; 1998 Feb; 178(2):300-4. PubMed ID: 9500490
[TBL] [Abstract][Full Text] [Related]
28. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
Creasy GW; Fisher AC; Hall N; Shangold GA
J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
[TBL] [Abstract][Full Text] [Related]
29. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
Olson WH; Lippman JS; Robisch DM
Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
Runnebaum B; Grunwald K; Rabe T
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1963-8. PubMed ID: 1605286
[TBL] [Abstract][Full Text] [Related]
31. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
[TBL] [Abstract][Full Text] [Related]
32. Less estrogen in new oral contraceptive.
Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
[No Abstract] [Full Text] [Related]
33. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Roy P; Jakate AS; Patel A; Abramowitz W; Wangsa J; Persiani S; Kapil R
J Clin Pharmacol; 2005 Mar; 45(3):329-36. PubMed ID: 15703367
[TBL] [Abstract][Full Text] [Related]
34. Optimum dosage of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol.
Lawson JS; Yuliano SE; Pasquale SA; Osterman JJ
Am J Obstet Gynecol; 1979 Jun; 134(3):315-20. PubMed ID: 377968
[TBL] [Abstract][Full Text] [Related]
35. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Brenner P
Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
[No Abstract] [Full Text] [Related]
36. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.
Abrams LS; Skee DM; Wong FA; Anderson NJ; Leese PT
J Clin Pharmacol; 2001 Nov; 41(11):1232-7. PubMed ID: 11697756
[TBL] [Abstract][Full Text] [Related]
37. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Patel G; King A; Dutta S; Korb S; Wade JR; Foulds P; Sumeray M
J Clin Pharmacol; 2016 Jan; 56(1):47-55. PubMed ID: 26120010
[TBL] [Abstract][Full Text] [Related]
39. Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants.
Bhardwaj R; Stringfellow JC; Morris B; Croop RS; Bertz RJ
Headache; 2023 May; 63(5):652-662. PubMed ID: 37140071
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.
Abrams LS; Skee DM; Natarajan J; Wong FA; Leese PT; Creasy GW; Shangold MM
J Clin Pharmacol; 2001 Dec; 41(12):1301-9. PubMed ID: 11762557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
